Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210036/S010

PerClot Absorbable Hemostatic Powder Accessory Tips

Baxter Healthcare Corporation · Decision date Nov 7, 2026

MEDTECHLEDGER EXPLANATIONP210036/S010

What did the FDA approve?

The FDA recorded an approval decision on 2026-11-07 for P210036/S010, a supplement to PerClot Absorbable Hemostatic Powder Accessory Tips held by Baxter Healthcare Corporation. The supplement was filed under the Normal 180 Day Track No User Fee category, with the recorded reason being a location change affecting a manufacturer, sterilizer, packager or supplier. The decision statement describes approval for a new manufacturing site.

This action covers a site change within the existing application rather than a new approval of the device itself. The product is listed under the non-collagen based absorbable hemostatic agent category, product code LMG, with specialties recorded as general and plastic surgery. The source record does not identify the specific facility, the manufacturing step affected, or any supporting documents, so the scope of the site change and any review basis remain unknown.

FDA approval order statement

approval for a new manufacturing site
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
General, Plastic Surgery
Decision date
Nov 7, 2026
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P210036/S010
Regulatory pathway
PMA supplement
Product code
LMG
Decision code
APPR
Decision date
Nov 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, non-collagen based.

Product code
LMG
FDA device class
3

For the original device and its historical approval scope, see PMA P210036. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P210036 · Original PMA

    PerClot Polysaccharide Hemostatic System

  2. P210036/S010 received

    Application receipt date recorded by FDA.

  3. P210036/S010 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P210036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210036

Product / regulatory recordCompanyPathwayDecision dateSource
Baxter Healthcare CorporationPMA approvalMay 19, 2023FDA

Explore the linked device profile

Other records with product code LMG

Product / regulatory recordCompanyPathwayDecision dateSource
ETHICON, Inc.PMA supplementNov 5, 2026FDA
ETHICON, Inc.PMA approvalOct 14, 1960FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Baxter Healthcare Corporation

Headquarters
Not reported
Brand website
baxter.com
FDA applicant address
25212 W. Illinois Rte. 120, Round Lake, IL, 60073

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records